Clinical Therapeutics

Olmesartan medoxomil: An angiotensin II-receptor blocker
pp. 1041-1055(15)
Authors: Brousil J.A.; Burke J.M.

Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: Results of two placebo-controlled trials
pp. 1056-1073(18)
Authors: Borenstein D.G.; Korn S.

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
pp. 1074-1095(22)
Authors: Herz M.; Johns D.; Reviriego J.; Grossman L.D.; Godin C.; Duran S.; Hawkins F.; Lochnan H.; Escobar-Jimenez F.; Hardin P.A.; Konkoy C.S.; Tan M.H.; GLAB Study Group

A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents
pp. 1096-1106(11)
Authors: Shulman D.G.; Amdahl L.; Washington C.; Graves A.

Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet
pp. 1107-1122(16)
Authors: Derosa G.; Mugellini A.; Ciccarelli L.; Fogari R.

Tramadol/Acetaminophen combination tablets for the treatment of chronic lower back pain: A multicenter, randomized, double-blind, placebo-controlled outpatient study
pp. 1123-1141(19)
Authors: Ruoff G.E.; Rosenthal N.; Jordan D.; Karim R.; Kamin M.; on behalf f the Protocol CAPSS-112 Study Group

A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: A double-blind, randomized, controlled trial
pp. 1142-1149(8)
Authors: Fujii Y.; Tanaka H.; Kawasaki T.

Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders
pp. 1150-1171(22)
Authors: Gianfrancesco F.; Grogg A.; Mahmoud R.; Wang R.-H.; Meletiche D.

Patient Persistency with ocular prostaglandin therapy: A population-based, retrospective study
pp. 1172-1185(14)
Authors: Reardon G.; Schwartz G.F.; Mozaffari E.

An analysis of cholesterol control and statin use in the losartan intervention for endpoint reduction in hypertension study
pp. 1186-1199(14)
Authors: Kristianson K.; Fyhrquist F.; Devereux R.B.; Kjeldsen S.E.; Lindholm L.H.; Lyle P.A.; Nieminen M.S.; Snapinn S.M.

An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir
pp. 1200-1210(11)
Authors: Gutierrez M.M.; Rosenberg J.; Abramowitz W.

Targeted etanercept for discogenic neck pain: Uncontrolled, open-label results in two adults
pp. 1211-1218(8)
Author: Tobinick E.L.

Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days: An in vitro study
pp. 1219-1225(7)
Authors: Laposata M.; Johnson S.M.

The complexity of assessing outcomes of combination therapy
pp. 1228-1229(2)
Author: Mullins C.D.

Timeliness of review and approval of new drugs in Canada from 1999 through 2001: Is progress being made?
pp. 1230-1247(18)
Author: Rawson N.S.B.

Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the heart outcomes prevention evaluation (HOPE) study
pp. 1248-1261(14)
Authors: Carroll C.A.; Coen M.M.; Rymer M.M.

A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999
pp. 1262-1275(14)
Authors: Ong M.; Catalano R.; Hartig T.

An economic assessment of the extent of medication use and wastage among families in Saudi Arabia and Arabian Gulf countries
pp. 1276-1292(17)
Author: Abou-Auda H.S.